Proton therapy developer Ion Beam Applications (IBA) has posted healthy revenue for 2016 (end-December 31).
Revenue for the company grew 21.6% to 328.7 million euros ($354.5 million U.S.), compared with 270.4 million euros ($291.6 million U.S.) in 2015.
The company attributed the revenue boost in part to the sale of five Proteus One and three Proteus Plus proton therapy systems, which brought in 228 million euros ($245.9 million U.S.).
The company's net profit for the year was 24.4 million euros ($26.3 million U.S.), down from 61.2 million euros ($66 million U.S.) in 2015, which IBA attributed to nonrecurring expenses such as reorganizational costs and a financial charge.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&fit=crop&h=100&q=70&w=100)
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
